Hologic, Inc. (HOLX)
Stock Price Chart
Key Info
| Market Cap | 17.58B |
| Revenue (ttm) | 3.78B |
| Net Income (ttm) | 1.12B |
| Shares Out | 257.01M |
| EPS (ttm) | 4.21 |
| PE Ratio | 16.24 |
| Forward PE | 20.04 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | November 30 |
| Last Price | $68.39 |
| Previous Close | $69.51 |
| Change ($) | -1.12 |
| Change (%) | -1.61% |
| Day's Open | 69.52 |
| Day's Range | 68.12 - 69.87 |
| Day's Volume | 352,842 |
| 52-Week Range | 29.38 - 76.67 |
More Stats
| Market Cap | 17.58B |
| Enterprise Value | 19.93B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 257.01M |
| Float | n/a |
| EPS (basic) | 4.24 |
| EPS (diluted) | 4.21 |
| FCF / Share | 2.82 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 6.16% |
| FCF Yield | 4.21% |
| Payout Ratio | n/a |
| Shares Short | 5.22M |
| Short Ratio | 2.41 |
| Short % of Float | n/a |
| Beta | 1.40 |
| PE Ratio | 16.24 |
| Forward PE | 20.04 |
| P/FCF Ratio | 23.75 |
| PS Ratio | 4.65 |
| PB Ratio | 6.60 |
| Revenue | 3.78B |
| Operating Income | 1.11B |
| Net Income | 1.12B |
| Free Cash Flow | 740.20M |
| Net Cash | -2.36B |
| Net Cash / Share | -9.17 |
| Gross Margin | 66.55% |
| Operating Margin | 29.26% |
| Profit Margin | 29.50% |
| FCF Margin | 19.60% |
| ROA | 10.61% |
| ROE | 46.05% |
| ROIC | 26.80% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,776 | 3,367 | 3,218 | 3,059 | 2,833 | 2,705 | 2,531 | 2,492 | 2,003 | 1,789 |
| Revenue Growth | 12.15% | 4.64% | 5.2% | 7.98% | 4.72% | 6.89% | 1.54% | 24.45% | 11.92% | - |
| Gross Profit | 2,228 | 1,171 | 1,697 | 1,621 | 1,563 | 1,433 | 1,246 | 1,161 | 994 | 923 |
| Operating Income | 1,105 | -124 | -238 | 471 | 549 | 455 | 280 | -895 | 152 | 366 |
| Net Income | 1,115 | -204 | -111 | 756 | 331 | 132 | 17.30 | -1,173 | -73.60 | 157 |
| Shares Outstanding | 263 | 269 | 275 | 280 | 280 | 281 | 275 | 269 | 264 | 261 |
| Earnings Per Share | 4.21 | -0.76 | -0.40 | 2.64 | 1.16 | 0.45 | 0.06 | -4.36 | -0.28 | 0.59 |
| EPS Growth | - | - | - | 127.59% | 157.78% | 650% | - | - | - | - |
| Operating Cash Flow | 897 | 650 | 733 | 8.30 | 798 | 797 | 508 | 494 | 370 | 456 |
| Capital Expenditures | -156 | -114 | -106 | -108 | -94.50 | -89.40 | -80.20 | -90.10 | -78.70 | -55.66 |
| Free Cash Flow | 740 | 536 | 627 | -99.30 | 704 | 707 | 428 | 404 | 292 | 400 |
| Cash & Equivalents | 701 | 602 | 667 | 541 | 548 | 493 | 742 | 829 | 566 | 713 |
| Total Debt | 3,058 | 3,076 | 3,327 | 3,347 | 3,345 | 3,612 | 4,268 | 4,806 | 5,036 | 1,489 |
| Net Cash / Debt | -2,357 | -2,474 | -2,660 | -2,807 | -2,797 | -3,120 | -3,526 | -3,977 | -4,469 | -776 |
| Assets | 7,196 | 6,442 | 7,231 | 7,980 | 7,317 | 7,643 | 8,415 | 9,001 | 10,477 | 6,009 |
| Liabilities | 4,489 | 4,326 | 4,802 | 5,195 | 5,174 | 5,563 | 6,352 | 7,059 | 7,516 | 3,072 |
| Book Value | 2,705 | 2,116 | 2,429 | 2,785 | 2,143 | 2,079 | 2,063 | 1,942 | 2,961 | 2,937 |
Company Profile
Company Details
| Full Name | Hologic, Inc. |
| Country | United States |
| Employees | 5,814 |
| CEO | Stephen P. MacMillan |
Stock Information
| Ticker Symbol | HOLX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NASDAQ: HOLX |
| IPO Date | June 21, 1990 |
Description
Hologic develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.